ArticleMolecular biology reports2025
Mechanism of hydroxychloroquine in the treatment of obstetric antiphospholipid syndrome by inhibiting NETs-induced trophoblast pyroptosis.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neutrophil extracellular traps in pregnancy complications.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Neutrophil extracellular traps (NETs) play a crucial role in the adverse pregnancy outcomes associated with obstetric antiphospholipid syndrome (OAPS). However, the mechanism by which NETs lead to placental dysfunction is unclear. Hydroxychloroquine (HCQ) represents a first-line therapy for refractory OAPS, yet data on its pharmacological effects are limited. Therefore, we investigated the protective function of HCQ and the pathological process of NETs in OAPS in relation to cell pyroptosis. The anti-β2GPI antibody induced significant NETs formation. Antiphospholipid antibody-induced NETs (aPL-NETs) induced significant in vivo and in vitro trophoblast pyroptosis and inflammatory cytokine release, which were improved following the administration of NET degradation agent DNaseI. Furthermore, mitochondrial reactive oxygen species were involved in aPL-NETs-induced trophoblast pyroptosis. HCQ significantly alleviated the trophoblast pyroptosis induced by aPL-NETs. Mechanistically, HCQ inhibited the abnormal activation of MAPK and NF-κB signaling pathways in trophoblast cells and promoted the expression of antioxidants. Our findings provide novel insights into the pyroptotic role of NETs in OAPS pathogenesis and reveal the potential therapeutic targets of HCQ, confirming its pharmacological effects. Furthermore, we suggest that oxidative stress is an important mediator of NETs involvement in OAPS placental dysfunction, providing theoretical support for follow-up studies.
Indexed as
Identifiers
40622503What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.